Leigh 综合征市场（2026—2031）
Leigh 综合征市场规模预计由2026年的82.8亿美元增至2031年的116.8亿美元，预测期复合年增长率为7.12%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
Leigh 综合征市场规模预计由2026年的82.8亿美元增至2031年的116.8亿美元，预测期复合年增长率为7.12%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 7.12% | 机构预测 |
| 市场规模 | 2026 | USD 8.28 billion | 机构预测 |
| 市场规模 | 2031 | USD 11.68 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| care_setting | Tertiary Hospitals | 2025 | 42.910% |
| genetic_etiology | Nuclear DNA-Associated Leigh Syndrome | 2025 | 58.240% |
| geography | North America | 2025 | 41.280% |
| route_of_administration | Oral administration | 2025 | 67.850% |
| treatment_type | Supportive & Symptomatic Therapy | 2025 | 46.370% |
关键结论
- care_setting 维度中，Tertiary Hospitals 在 2025 年的公开份额为 42.91%。
- genetic_etiology 维度中，Nuclear DNA-Associated Leigh Syndrome 在 2025 年的公开份额为 58.24%。
- geography 维度中，North America 在 2025 年的公开份额为 41.28%。
- route_of_administration 维度中，Oral administration 在 2025 年的公开份额为 67.85%。
- treatment_type 维度中，Supportive & Symptomatic Therapy 在 2025 年的公开份额为 46.37%。
主要参与者
- Thiogenesis Therapeutics, Inc.
- PTC Therapeutics, Inc.
- Abliva AB
- Stealth BioTherapeutics Corp.
- Taysha Gene Therapies, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Increasing Genetic Testing and Earlier Diagnosis | +1.200% | Global, with early gains in North America and Western Europe | Short term (≤ 2 years) |
| Expansion of Rare Mitochondrial Disease Research Funding | +0.900% | North America and EU | Medium term (2-4 years) |
| Progress in Mitochondrial Targeted and Gene Therapies | +1.500% | North America, EU, and Japan | Long term (≥ 4 years) |
| Growth of Patient Registries and Trial Ready Cohorts | +0.700% | Global, concentrated in North America and Europe | Medium term (2-4 years) |
| Increasing Clinical Recognition of Leigh Syndrome | +0.600% | Global, pronounced in Asia-Pacific and Middle East and Africa | Short term (≤ 2 years) |
| Mutation Specific Drug Repurposing and Precision Screening | +0.800% | North America and EU | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Genetic and Phenotypic Heterogeneity | -1.200% | Global | Long term (≥ 4 years) |
| High Cost of Rare Disease Drug Development | -0.900% | Global, with greater burden in emerging markets | Long term (≥ 4 years) |
| Delayed Diagnosis and Limited Specialist Access | -0.600% | Asia-Pacific, Middle East and Africa, and South America | Medium term (2-4 years) |
| Weak Commercial Incentives for Ultra Rare Subgroups | -0.800% | Global | Medium term (2-4 years) |
报告关注的关键问题
What is the projected value of the Leigh syndrome market in 2031?
The Leigh syndrome market is forecast to reach USD 11.68 billion by 2031, growing at a 7.12% CAGR from 2026.
Which treatment category is growing fastest for Leigh syndrome?
Gene & RNA-Based Therapies are forecast to grow at a 24.86% CAGR through 2031.
Why are genetic tests important for Leigh syndrome care?
Genetic confirmation identifies disease subtypes earlier and helps match eligible patients with specialist care and clinical trials. This diagnostic pathway makes the Leigh syndrome market more accessible to programs that need genetically defined and clinically documented participants for study enrollment.
Which administration route is most widely used for Leigh syndrome treatment?
Oral administration held 67.85% in 2025 because cofactor supplementation and small-molecule therapies are commonly used.
Which region is expected to grow fastest through 2031?
Asia-Pacific is forecast to expand at a 15.38% CAGR through 2031, supported by increasing clinical research and genetic testing capacity.
What is the main challenge for drug developers in Leigh syndrome?
More than 100 causative genes divide the patient population, making mutation-specific trial recruitment and commercial planning difficult. Small cohorts must still support manufacturing, safety monitoring, regulatory reporting, and meaningful clinical evidence for each separate development program.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence